SCHEMBL26075885

SCHEMBL26075885

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(P)ccc4n3)cc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HMOX1 P09601 3/20 0.41
▸ KDM4E B2RXH2 6/20 0.41
▸ RAB9A P51151 6/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ LMNA P02545 5/20 0.41
▸ NPC1 O15118 4/20 0.41
▸ HPGD P15428 4/20 0.41
▸ GAA P10253 1/20 0.40
▸ HSD17B10 Q99714 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPT P10636 2/20 0.37
▸ TP53 P04637 5/20 0.37
▸ USP2 O75604 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ CTNNB1 P35222 1/20 0.37
▸ ESR1 P03372 2/20 0.36
▸ ESR2 Q92731 2/20 0.36
▸ FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075888 0.94 HMOX1 (0.43) HMOX1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL26075902 0.92 NCF1 (0.37) HMOX1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL26075867 0.92 PLA2G2A (0.42) HMOX1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL26075866 0.92 DHODH (0.43) ACACA
SCHEMBL26075876 0.90 PTGS2 (0.45) HMOX1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL26075877 0.90 PLA2G2A (0.41) KDM4ERAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL26075130 0.89 HMOX1 (0.43) HMOX1KDM4ERAB9AALDH1A1SMN1; SMN2
SCHEMBL26075868 0.89 PLA2G2A (0.41) KDM4ERAB9AALDH1A1SMN1; SMN2NPC1
SCHEMBL26075871 0.89 ALOX5AP (0.39) HMOX1RAB9ASMN1; SMN2NPC1GAA
SCHEMBL26075865 0.88 ACACA (0.46) KDM4ERAB9AALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD HMOX1 329/4885KDM4E 1396/4885RAB9A 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback